AAO '25: GLP-1s and AMD, and Parity in Retina Care

Late-Breaking Talks at AAO '25: Phase 3 for Uveitic Macular Edema and GATHER2 OLE

AAO '25: Dry AMD Pipeline and Oral Treatment for Stargardt Disease

The Nuts and Bolts of GA Therapy: The Discussions Continue

Late-Breaking Talks at AAO '25: Gene Therapy for RP and NPDR

New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient Care

The Nuts and Bolts of GA Therapy: The Opening Sessions

Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring Vision

Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and Photobiomodulation

Keeping Patients at the Center of GA Therapy: Patient Education and Setting Expectations

Keeping Patients at the Center of GA Therapy: Social Impact and Early Intervention

New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From Faricimab

ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDR

ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human Graders

New Retina Radio Journal Club w/ VBS: Obstructive Sleep Apnea and Diabetic Retinopathy

The State of Geographic Atrophy Around the Globe: Part 2 of 2

The State of Geographic Atrophy Around the Globe: Part 1 of 2

Diabetic Retinopathy Severity and Income Status

GA in 2025: Conversion to Wet AMD and Educating Patients on the Value of Continuing Therapy

GA in 2025: Dosing Regimens, Drug Selection, and Ideal Candidates